Artiva Biotherapeutics, Inc. (ARTV)
NASDAQ:ARTV
Want to see ARTV full AI Analyst Report?
ARTV Stock Chart & Stats
$12.55
$0.32(3.02%)
At close: 4:00 PM EST
$12.55
$0.32(3.02%)
Day’s Range― - ―
52-Week Range$1.47 - $14.53
Previous CloseN/A
Volume23.16K
Average Volume (3M)676.13K
Market Cap
$211.08M
Enterprise Value$185.31M
Total Cash (Recent Filing)$86.78M
Total Debt (Recent Filing)$10.26M
Price to Earnings (P/E)―
Beta2.30
Next Earnings
Aug 27, 2026EPS Estimate
-0.63Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.55
Shares Outstanding24,716,673
10 Day Avg. Volume659,411
30 Day Avg. Volume676,127
Financial Highlights & Ratios
PEG Ratio0.04
Price to Book (P/B)0.95
Price to Sales (P/S)0.00
P/FCF Ratio-1.32
Enterprise Value/Market Cap0.88
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-278.25
Enterprise Value/Ebitda-2.19
Forecast
1Y Price Target
$35.80Price Target Upside185.26% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
EPS Forecast (FY)-2.67
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
FDA Phase 3 Alignment For AlloNKRegulatory agreement on a single Phase 3 registrational trial materially reduces protocol risk and provides a clear pathway to a potential BLA. This structural clarity allows management to prioritize resources, plan endpoints and timelines, and increases the persistency of development value over the next 2–6 months.
Strong AlloNK Efficacy And TolerabilityHigh response rates with a favorable safety profile in refractory autoimmune patients indicate clinical differentiation and lower regulatory/commercial risk. Durable positive signals across indications can improve trial success probability, partner interest and the long-term commercial potential of an allogeneic NK platform.
Substantial $300M Capital RaiseA $300M equity offering materially increases execution funding, extending the company's ability to complete registrational activities and multiple trials without immediate asset sales. While dilutive, the financing structurally strengthens runway and supports strategic development and partnership options over the medium term.
Bears Say
Persistent High Cash Burn And Constrained RunwayOperating cash outflows are large and recurring, meaning the business depends on capital markets to fund operations. Even with financing actions, sustained negative FCF implies periodic dilution risk and limited margin for trial delays or setbacks, pressuring long-term financial flexibility and strategic optionality.
Absent Material Recurring RevenueLack of product revenue leaves the company fully reliant on external funding and milestones. This structural absence of recurring cash inflows reduces resilience to clinical setbacks, increases funding dependency, and limits the firm's ability to self-finance development or invest in commercialization infrastructure.
Executive Turnover And Role ConsolidationConsolidation of CFO duties into the CEO and recent board/executive shifts create governance and execution risk. Such leadership changes can distract management, complicate financial oversight during critical trial and financing periods, and may slow strategic decisions or investor confidence over the medium term.
Artiva Biotherapeutics, Inc. News
ARTV FAQ
What was Artiva Biotherapeutics, Inc.’s price range in the past 12 months?
Artiva Biotherapeutics, Inc. lowest stock price was $1.47 and its highest was $14.53 in the past 12 months.
What is Artiva Biotherapeutics, Inc.’s market cap?
Artiva Biotherapeutics, Inc.’s market cap is $211.08M.
When is Artiva Biotherapeutics, Inc.’s upcoming earnings report date?
Artiva Biotherapeutics, Inc.’s upcoming earnings report date is Aug 27, 2026 which is in 73 days.
How were Artiva Biotherapeutics, Inc.’s earnings last quarter?
Artiva Biotherapeutics, Inc. released its earnings results on May 08, 2026. The company reported -$0.95 earnings per share for the quarter, missing the consensus estimate of -$0.87 by -$0.08.
Is Artiva Biotherapeutics, Inc. overvalued?
According to Wall Street analysts Artiva Biotherapeutics, Inc.’s price is currently Undervalued.
Does Artiva Biotherapeutics, Inc. pay dividends?
Artiva Biotherapeutics, Inc. does not currently pay dividends.
What is Artiva Biotherapeutics, Inc.’s EPS estimate?
Artiva Biotherapeutics, Inc.’s EPS estimate is -0.63.
How many shares outstanding does Artiva Biotherapeutics, Inc. have?
Artiva Biotherapeutics, Inc. has 24,716,673 shares outstanding.
What happened to Artiva Biotherapeutics, Inc.’s price movement after its last earnings report?
Artiva Biotherapeutics, Inc. reported an EPS of -$0.95 in its last earnings report, missing expectations of -$0.87. Following the earnings report the stock price went down -13.019%.
Which hedge fund is a major shareholder of Artiva Biotherapeutics, Inc.?
Currently, no hedge funds are holding shares in ARTV
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Artiva Biotherapeutics, Inc. Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$35.80 (185.26% Upside)
$35.80 (185.26% Upside)
Blogger Sentiment
Bullish
ARTV Sentiment 70%
Sector Average ―
Sector Average ―
Insider Transactions
Bought Shares
Worth $98.7M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Positive
Last 7 Days ▼ 0.2%
Last 30 Days ▲ 3.2%
Last 30 Days ▲ 3.2%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
316.58%
12-Months-Change
Fundamentals
Return on Equity
-73.16%
Trailing 12-Months
Asset Growth
-44.60%
Trailing 12-Months
Company Description
Artiva Biotherapeutics, Inc.
Artiva Biotherapeutics, Inc. is a clinical-stage biotechnology firm specializing in the development of natural killer (NK) cell-based treatments for individuals afflicted with autoimmune disorders and various forms of cancer. Its flagship therapeutic candidate, AB-101, is an innovative, ready-to-use (off-the-shelf) NK cell therapy. This treatment is being developed for a broad spectrum of conditions, including autoimmune diseases like lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, systemic lupus erythematosus, and specific anti-neutrophil cytoplasmic antibody-associated vasculitis subtypes such as granulomatosis with polyangiitis/microscopic polyangiitis, in addition to B-cell non-Hodgkin lymphoma. The company's pipeline also includes AB-201, an allogeneic anti-human epidermal growth factor receptor 2 chimeric antigen receptor (CAR)-NK cell candidate, and AB-205, another allogeneic anti-CD5 CAR-NK cell candidate. Established in 2019, Artiva Biotherapeutics is headquartered in San Diego, California.
ARTV Stock 12 Month Forecast
Average Price Target
$35.80
▲(185.26% Upside)
Technical Analysis
Ownership Overview
77.66% Insiders
2.18% Mutual Funds
0.90% Other Institutional Investors
17.94% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---